Intestinal Candida parapsilosis isolates from Rett syndrome subjects bear potential virulent traits and capacity to persist within the host

Table 1 Antifungals resistance of Candida isolates from HC or RTT patients

Species	Antifungals	Healthy controls (HC)				Rett syndrome (RTT) subjects
		MIC (μg/ml)		^aCBPs		MIC (μg/ml)		^aCBPs
		MIC₅₀	MIC₉₀	%S	%R	MIC₅₀	MIC₉₀	%S	%R
C. albicans	Fluconazole	0.5	> 64	75.6	24.4	1	2	75	25
	Itraconazole	0.25	> 8	36.6	63.4	0.0156	0.0156	100	0
	5-Flucytosine	0.125	0.5	97.6	2.4	0.125	0.125	100	0
C. parapsilosis	Fluconazole	0.5	2	92.9	7.1	2	> 64	64.3	35.7
	Itraconazole	0.0156	0.125	100	0	0.0156	> 8	64.3	35.7
	5-Flucytosine	0.125	0.5	100	0	0.125	0.125	100	0
^b Candida spp.	Fluconazole	0.125	0.25	100	0	> 64	> 64	0	100
	Itraconazole	0.0156	0.0156	100	0	8	8	0	100
	5-Flucytosine	0.125	0.125	100	0	0.125	0.125	100	0

^aAccording to EUCAST recommendations; S sensible; R Resistant; MIC ranges: Fluconazole 0.125–64 μg/ml; Itraconazole 0.0156–8 μg/ml; 5-Flucytosine 0.125–64 μg/ml. ^bCandida spp. isolated from RTT subjects (i.e. C. glabrata, C. pararugosa and C. tropicalis); Candida spp. isolated from HC (i.e. C. deformans, C. intermedia and C. lusitaniae)

ISSN: 1471-230X